Surgical outcomes of XEN45 implantation, trabeculectomy vs. penetrating canaloplasty in open-angle glaucoma: A non-randomized comparative study
Haishuang Lin,Wenzhe Zhou,Jinxin Li,Wenqing Ye,Xuanli Zheng,Changrong Lei,Jiaqian Li,Rui Wan,Ningli Wang,Yuanbo Liang
DOI: https://doi.org/10.1097/cm9.0000000000003128
IF: 6.133
2024-08-21
Chinese Medical Journal
Abstract:To the Editor: Glaucoma is a leading cause of irreversible blindness worldwide. [ 1 ] Trabeculectomy with mitomycin C (MMC) has been the standard surgical intervention for reducing intraocular pressure (IOP) and slow down the progression of glaucoma. [ 2 ] However, some serious complications with devastating consequences can occur after trabeculectomy, such as bleb-related infections, suprachoroidal hemorrhage, vitreous hemorrhage, and malignant glaucoma. Over the last decade, many novel ophthalmic surgical devices have been used in glaucoma. The XEN45 microstent (Allergan, Dublin, CA, USA) is a hydrophilic cross-linked porcine gelatin stent. It is implanted ab-interno, draining the aqueous humor into the subconjunctival space without the need to form a conjunctival flap, scleral flap, or iridectomy. Penetrating canaloplasty (PCP), first proposed by Liang et al [ 3 ] , is a relatively new Schlemm's canal-based surgery. The procedure integrates the trabeculectomy procedures into canaloplasty, creating a direct communication between the anterior chamber and the ostia of Schlemm's canal to restore the internal drainage of aqueous humor. PCP restores the aqueous humor outflow in a bleb-independent manner and does not require MMC. The purpose of this study is to compare the surgical success and postoperative complications among XEN45 implantation, trabeculectomy with MMC, and PCP in Chinese patients with open-angle glaucoma over a 12-month period.
medicine, general & internal